Compositions and methods for immune cell modulation in adoptive immunotherapies
Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
1. A method of treating a human subject in need thereof, the method comprising administering to the human subject a therapeutic composition comprising a population of modulated immune cells, wherein:
(a) the modulated immune cells are cells produced by culturing a population of immune cells in a culture medium to produce the modulated population of immune cells, wherein
(i) the culturing comprises inhibiting BCR-ABL tyrosine kinase; and
(ii) the culturing increases the number or ratio of one or more subpopulations comprising T cells expressing one or both of CD62L and CCR7; and
(b) the therapeutic composition comprises the T cells expressing one or both of CD62L and CCR7 in a therapeutically sufficient amount for adoptive cell therapy in said human subject in need thereof.
2. The method of claim 1 , wherein the therapeutic composition is prepared by isolating the one or more subpopulations.
3. The method of claim 1 , wherein the T cells comprise naïve T cells, stem cell memory T cells, or central memory T cells.
4. The method of claim 1 , wherein the population of immune cells are isolated from or comprised in peripheral blood, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
5. The method of claim 1 , wherein the population of immune cells are isolated from
(a) a healthy subject; or
(b) a subject having an autoimmune disease, a hematopoietic malignancy, a virus infection or a solid tumor.
6. The method of claim 1 , wherein the population of immune cells
(a) are differentiated from stem cells, hematopoietic stem or progenitor cells, or progenitor cells; or
(b) are trans-differentiated from a non-pluripotent cell of non-hematopoietic lineage.
7. The method of claim 6 , wherein the stem cells are induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).
8. The method of claim 6 , wherein the progenitor cells are multipotent progenitor cells or T cell progenitor cells.
9. The method of claim 6 , wherein the stem cells, hematopoietic stem or progenitor cells, or progenitor cells
(a) are genomically engineered and comprise an insertion, a deletion, or a nucleic acid replacement; or
(b) comprise an exogenous nucleic acid encoding a T Cell Receptor (TCR) and/or a Chimeric Antigen Receptor (CAR).
10. The method of claim 1 , wherein the population of immune cells
(a) are genomically engineered and comprise an insertion, a deletion, or a nucleic acid replacement; or
(b) comprise an exogenous nucleic acid encoding a T Cell Receptor (TCR) and/or a Chimeric Antigen Receptor (CAR).
11. The method of claim 1 , wherein inhibiting the BCR-ABL tyrosine kinase comprises contacting the population of immune cells with DCC-2036 (Rebastinib) in the culture medium.
12. The method of claim 1 , wherein the T cells have at least one of:
(a) increased gene expression in CD27;
(b) decreased gene expression in at least one of PD-1 and Tim-3;
(c) increased central memory T cell subpopulation; or
(d) decreased effector T cell subpopulation;
in comparison to T cells cultured without inhibiting the BCR-ABL tyrosine kinase.
13. The method of claim 1 , wherein the T cells are CAR-T cells.
14. The method of claim 1 , wherein the T cells comprise T cells that are CD8 + or CD4 + .